<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561039</url>
  </required_header>
  <id_info>
    <org_study_id>ML20713</org_study_id>
    <nct_id>NCT02561039</nct_id>
  </id_info>
  <brief_title>A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease</brief_title>
  <official_title>Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of ibandronate (Bondronat), administered
      intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate
      to severe pain. Participants will be randomized to receive ibandronate either as a 6-mg IV
      infusion every 3 to 4 weeks or a 50-mg tablet PO daily. Pain response and Karnofsky
      Performance Index (KPI) will be measured at intervals throughout the study. The anticipated
      time on study treatment is 4 months and the target sample size is 150 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate according to reduction in BPI most acute pain score from Baseline</measure>
    <time_frame>Month 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in KPI</measure>
    <time_frame>Baseline to Month 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of decrease in most acute pain score</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption according to participant diary</measure>
    <time_frame>Up to 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Pain; Bone Neoplasms; Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Ibandronate IV Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibandronate PO Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ibandronate, 50 mg PO daily, for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.</description>
    <arm_group_label>Ibandronate IV Infusion</arm_group_label>
    <arm_group_label>Ibandronate PO Tablet</arm_group_label>
    <other_name>Bondronat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults at least 18 years of age

          -  Malignant bone disease due to multiple myeloma or cancer of the lung, prostate,
             gastrointestinal (GI) tract, ovary, or bladder

          -  Bone pain defined as a Brief Pain Inventory (BPI) most acute pain score greater than
             or equal to 4

          -  Radiologically confirmed bone disease disease

        Exclusion Criteria:

          -  Previous treatment with ibandronate (Bondronat) within previous 2 months

          -  Severely impaired renal function

          -  Known brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bourgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1757</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vratza</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

